Dublin, Aug. 17, 2022 (GLOBE NEWSWIRE) — The “Cell Analysis Global Market – Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering.
According to analysis, the cell analysis global market is expected to grow at a low single digit CAGR from 2022 to 2029 to reach $38,020.6 million by 2029. The rising incidence of infectious and non-infectious diseases and demand for early detection, diagnosis & treatment, increasing government and private funding towards cell based research, increasing advancements in cell imaging technologies to reduce the cost & time during the drug discovery process are driving the cell analysis market.
The market for cell analysis is segmented based on technique, product, application, end-user and geography. The cell analysis techniques global market is segmented into PCR, Sequencing, Microfluidics and Microarrays, Spectrometry, Microscopy, Cytometry, High Content Analysis, Electrophoresis and Others. Among the techniques, the PCR segment accounted for the largest revenue in 2022. The Sequencing segment is expected to grow at a double digit CAGR from 2022 to 2029.
The cell analysis products market is mainly segmented into consumables, instruments, software and services. Among these, consumables segment commanded the largest revenue in 2022 and is expected to grow at a low single digit CAGR from 2022 to 2029. The software and services segment is expected to grow at a mid single digit CAGR from 2022 to 2029.
The consumables market is further sub-segmented into reagents, assay kits, microplates and others. Among the consumables sub-segments, the assay kits held the largest revenue in 2022. Reagents sub-segment is the fastest growing segment with a mid single digit CAGR from 2022 to 2029.
The application market is categorized based on processes, field, and by therapeutic area. In the process of application, the market is segmented into cellular processes, signal transduction pathways, circulating tumor cells, single-cell analysis, epigenetic target analysis, subpopulation characterization, and drug and candidate screening.
Based on field of application, the market is further segmented into forensic, therapeutics, cell imaging, biomarker research, genomic analysis, stem cell analysis, and diagnostics. Diagnostics held the largest revenue of in 2022. Stem cell analysis is the fastest-growing segment at a mid single digit from 2022 to 2029.
The end-users market is segmented into hospitals & diagnostic laboratories, academic and research institutes, contract research organizations (CROs), pharmaceuticals and biotechnology companies, cell banks, and others.
Drivers and Opportunities
Rising Incidence of Infectious and Non-Infectious Diseases and Demand for Early Detection, Diagnosis & Treatment
Increasing Government and Private Funding
Increasing Advancements in Cell Imaging Technologies Reduce the Cost and Time Consumption for the Drug Discovery Process
Growing Focus on Personalized Medicine
Introduction of Advanced Technologies in Cell Analysis
Increasing Merger and Acquisition Activities in Cell Analysis
Restraints & Threats
Lack of Skilled Personnel to Use Advanced Cell Analysis Instruments
Expensive Cell Analysis Instruments
Maintaining Consistency, Reproducibility of Assays and Lack of Standardization
Availability of Alternative Technologies
Stringent Regulatory Framework Limits Advancements in Cellular Analysis Market
Key Topics Covered:
1 Executive Summary
3 Market Analysis
4 Cell Analysis Global Market, Based on Techniques
5 Cell Analysis Global Market, Based on Products
6 Cell Analysis Global Market, Based on Application
7 Cell Analysis Global Market, Based on End-Users
8 Regional Market Analysis
9 Competitive Landscape
10 Major Player Profiles
Abbott Laboratories, Inc.
ABP Biosciences LLC
Adaptive Biotechnologies Corp.
Agilent Technologies Inc. (U.S.)
Akadeum Life Sciences
Akoya Biosciences, Inc.
Alit Lifesciences Co., Ltd
Altona Diagnostics GmbH
Analytik Jena AG (CyBio AG)
ArrayGen Technologies Pvt Ltd (India)
Art Robbins Instruments LLC (U.S.)
Aviva Bioscience (U.S.)
Axion Biosystems (CytoSMART Technologies B.V.) (U.S.)
Azenta Life Sciences (Brooks life sciences)
Becton Dickinson and Company
Berry Genomics Co., Ltd
Bio View Ltd.
BioAgilytix Labs, LLC (Cambridge Biomedical Inc.)
Bio-Rad Laboratories Inc.
Carl Zeiss AG
GC biotech B.V.
Helena Laboratories Corporation
Hettich Lab Technology
Jasco Analytical Instruments
Kinetic River Corp.
LABGENE Scientific SA
LGC Ltd (Biosearch Technologies)
LungLife AI, Inc
Meiji Techno Co., Ltd
Menarini Silicon Biosystems
Micro-Shot Technology Ltd.
Miltenyil Biotec GmbH
Mission Bio, Inc.
Myllia Biotechnology (Aelian Biotechnology)
NanoString Technologies, Inc.
Scipio bioscience S.A.S
Single Cell Discoveries
Singleron Biotechnologies. Inc
Singular Genomics Systems, Inc
Tracxn Technologies Limited (Capp Aps)
Visitron Systems GmbH
Yokogawa Electric Corporation
For more information about this report visit https://www.researchandmarkets.com/r/3x17g2
In the world of stock legends, George Soros stands out. While his political activities have been a lightning rod for controversy, no one can doubt his financial acumen. After all, he’s the ‘man who broke the Bank of England,’ and made a billion dollars in one day when he shorted the Pound Sterling back in 1992. His hedge fund, Soros Fund Management, showed three decades of sustained gains, averaging 30% annual returns through the year 2000. During this time, and today in the management of his pe
Oil stocks and chemicals dominate this list of today's fastest-growing stocks, all eyeing 111%-762% EPS gains this year.
There's a bond that pays a 9.62% interest rate and is guaranteed by the U.S. Treasury. Investors should keep some limitations and conditions in mind before investing, but as inflation has topped 8% since March 2022, this could be an … Continue reading → The post Want 9.62% Yield Guaranteed? Seriously, Try This Asset appeared first on SmartAsset Blog.
Investors on the hunt for safe dividends should consider the Dividend Kings, a group of just 45 stocks that have increased their dividends for at least 50 consecutive years. Of the Dividend Kings, three in particular have high yields above 4% and safe dividends. AbbVie Inc. is a pharmaceutical company spun off by Abbott Laboratories in 2013.
Markets correspondent Jared Blikre takes a look at the declining pricing for cryptocurrencies bitcoin and ethereum as the FDIC issue letters to five crypto companies.
Scott Burg, the chief investment officer of Deer Park Road Management Co, who made the prediction that Tesla would be "squashed like a bug" in a 2020 tweet, bought put options on almost 4.8 million Tesla shares during the second quarter, according to a regulatory filing this week, Bloomberg and Barron's reported.
The real estate investment platform backed by Amazon.com Inc (NASDAQ: AMZN) founder Jeff Bezos has continued ramping up its acquisitions of single-family rental homes in several U.S. markets. Arrived Homes acquires single-family homes to use as rental properties, then sells shares of these properties to investors through its online platform. The demand for rental property shares has grown exponentially so far in 2022, with more homes funded in July than the entire first quarter. The company has
The market rally is retreating as the 10-year yields runs higher, toward 3%. Warren Buffett stock Occidental Petroleum surged Friday.
Back up the EV on shares of General Motors, says this one analyst.
One of the big reasons for investing in real estate investment trusts (REITs) is the kind of dividends many pay. While Treasury bonds are just beginning to catch up with inflation, some REITs offer better yields as long as investors are willing to accept the risks attached to owning them. Here are seven REITs with better-than-average, hard-to-ignore dividend yields: AGNC Investment Corp. (NASDAQ: AGNC) is paying 11.36% at a price of $12.57. The Bethesda, Maryland-based company specializes in res
Microsoft co-founder Bill Gates bought $32 million more of shares of Ecolab, a provider of water-treatment and hygiene goods and services.
Warren Buffett parks most of Berkshire Hathaway’s cash in ultrasafe U.S. Treasury bills. Here’s why you might want to do the same.
July and August were good months for equity bulls. But the bears might soon retake the upper hand, one Wall Street strategist warned.
The stock market might be at a crossroads once again. In recent weeks, we’ve seen some solid gains, mostly across the board, as a rally has taken hold and moderated year-to-date losses on the major indexes. But is this rally running out of steam? Taking the bearish view of the current environment is Morgan Stanley’s chief US equity strategist Mike Wilson. He sees the gains right now as a bear market rally, and believes that markets will likely turn down again in the longer term. Laying out his p
(Bloomberg) — A gulf has opened up between Chinese stocks and the rest of emerging-market equities in recent weeks as pandemic recoveries have diverged. That parting of ways is likely to be short-lived, fund managers say.Most Read from BloombergUS Mortgage Lenders Are Starting to Go BrokeUkraine Latest: Crimea Drone; US Sanctions Warning to TurkeyMueller Memo Advising Barr on Trump Findings Is Ordered ReleasedWhite House Says Zelenskiy Should Join G-20 If Putin AttendsHow to Beat Hedge Funds at
The pandemic isn’t over. These stocks could pop again.
In this article, we discuss the 5 stocks that Warren Buffett is buying on the dip. If you want to see more stocks in this selection, click Warren Buffett is Buying the Dip on These 3 Stocks. Berkshire Hathaway’s Warren Buffett went on a buying spree despite the turmoil in the global equity markets. In […]
Ryan Cohen became a figurehead for the movement in Bed Bath & Beyond (NASDAQ: BBBY) shares, first announcing a stake of 9.8% in the retailer. New filings later revealed Cohen owned an 11.8% stake in Bed Bath that included stock and options. On Thursday, it was revealed that Cohen sold his entire position in the struggling retailer. Cohen’s profit on the stake in the retailer was $68.1 million in seven to eight months time. Compare that to Jake Freeman, the 20-year-old college student who reporte
(Reuters) -Investors flooded social media platforms such as Reddit on Friday with criticism of Ryan Cohen's sale of his stake in Bed Bath & Beyond Inc, blaming him for helping fuel a meme stock rally only to then walk away with a $60 million profit. The billionaire investor disclosed on Thursday he had sold his 9.8% stake in the struggling home goods retailer almost five months after amassing it and pushing for changes. Cohen stands to earn a profit before taxes of between $55 million and $60 million on the stock sale, according to a Reuters review of regulatory filings and a person familiar with the matter.
Nvidia stock has recovered a bit after a revenue warning, but the chip bellwether remains firmly entrenched below its 200-day moving average.